DCT

2:26-cv-12063

Shionogi Inc v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-12063, D.N.J., 09/14/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Zydus USA has a regular and established place of business in the state and has committed acts of infringement there. The foreign-domiciled defendants may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's RADICAVA ORS® product constitutes an act of patent infringement.
  • Technical Context: The technology concerns a pharmaceutical formulation of edaravone as an oral suspension for the treatment of Amyotrophic Lateral Sclerosis (ALS), offering a more convenient administration route than previous intravenous methods.
  • Key Procedural History: This action is a Hatch-Waxman suit triggered by Defendants' ANDA filing and Paragraph IV certification. Plaintiff Shionogi recently acquired the RADICAVA ORS® assets from Tanabe Pharma Corporation in April 2026. The complaint notes numerous other pending patent litigations in the district involving the same drug, indicating a complex and active enforcement landscape. The FDA granted RADICAVA ORS® seven years of Orphan Drug Exclusivity, set to expire on May 12, 2029.

Case Timeline

Date Event
2018-11-02 '586 Patent Priority Date
2022-05-12 FDA approves RADICAVA ORS® (NDA No. 215446)
2022-08-05 Zydus USA submits FOIA request for RADICAVA ORS® approval summary
2024-03-28 FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-04-25 First of several related patent infringement actions filed concerning RADICAVA ORS®
2025-12-22 Shionogi announces agreement to acquire RADICAVA ORS® business
2026-04-01 Shionogi acquisition of RADICAVA ORS® assets becomes effective
2026-04-14 U.S. Patent No. 12,599,586 issues
2026-07-29 Zydus sends Paragraph IV Notice Letter regarding its ANDA
2026-09-14 Complaint filed
2029-05-12 Orphan Drug Exclusivity for RADICAVA ORS® expires

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Patent No. 12,599,586, "Edaravone suspension for oral administration", issued on April 14, 2026 (the "’586 Patent"). Compl. ¶38

U.S. Patent No. 12,599,586 - "Edaravone suspension for oral administration"

The Invention Explained

  • Problem Addressed: The patent background acknowledges edaravone as a therapeutic agent for ALS but notes that existing administration methods, such as intravenous (IV) injection, are burdensome for patients and caregivers, particularly for a chronic condition like ALS Compl. ¶11 ’586 Patent, col. 25:9-14 Developing a liquid oral formulation is challenging due to edaravone's low solubility in water, which can lead to poor bioavailability compared to an injection ’586 Patent, col. 25:1-9
  • The Patented Solution: The invention is an oral suspension that provides high bioavailability comparable to an IV injection ’586 Patent, col. 7:36-49 It achieves this by using a specific combination of components, including edaravone particles within a defined size range, water, and a "dispersant" such as polyvinyl alcohol ’586 Patent, abstract ’586 Patent, col. 26:57-28:2 The dispersant is key to maintaining the edaravone particles in a stable, solid, and well-dispersed state, preventing them from clumping and ensuring a uniform, effective dose in a small volume ’586 Patent, col. 4:1-9
  • Technical Importance: An effective oral formulation that is bioequivalent to an IV drug represents a significant improvement in patient quality of life and medication adherence, especially for patients with degenerative diseases who may have difficulty traveling to healthcare facilities for infusions Compl. ¶¶11-12

Key Claims at a Glance

  • The complaint asserts infringement of at least independent claim 1 Compl. ¶47
  • The essential elements of independent claim 1 are:
    • An edaravone suspension for human oral administration comprising water, edaravone particles dispersed in the water, and a dispersant that maintains the particles in a solid state.
    • The suspension is prepared by a process that includes mixing edaravone particles with a specific size distribution: a D50 particle size of 10 µm to 50 µm and a D90 particle size of 50 µm to 200 µm.
    • The edaravone particles must have a dissolution rate of 80% or more within 30 minutes, according to a specified test method from the Japanese Pharmacopoeia.
  • The complaint alleges infringement of "one or more claims," suggesting the right to assert additional dependent claims is preserved Compl. ¶47

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' proposed generic edaravone oral suspension, for which they submitted Abbreviated New Drug Application (ANDA) No. 220849 to the FDA Compl. ¶2

Functionality and Market Context

  • The complaint alleges that Zydus's product is a "proposed generic copy" of Shionogi’s RADICAVA ORS® Compl. ¶42 It is described as an "edaravone suspension, administered at a dose concentration of 105 mg/5 mL" Compl. ¶40
  • As an ANDA product, its purpose is to be a bioequivalent and therapeutically equivalent substitute for the branded reference drug, RADICAVA ORS®, for the treatment of ALS Compl. ¶41 The complaint alleges that upon approval, Zydus intends to commercially manufacture, market, and sell this product in the United States Compl. ¶49
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed claim chart, which is common in ANDA litigation filed shortly after receipt of a Paragraph IV notice. The infringement theory is based on the premise that in filing an ANDA for a bioequivalent copy of RADICAVA ORS®, the Defendants' proposed product will necessarily meet the limitations of the asserted claims.

’586 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An edaravone suspension for human oral administration, comprising: water; edaravone particles comprising edaravone and dispersed in the water; and a dispersant... The complaint alleges Zydus seeks approval for a proposed "edaravone suspension," which is a bioequivalent copy of the aqueous RADICAVA ORS® product. ¶40; ¶42 col. 2:12-16
wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm... The complaint does not provide specific data on the particle size of Zydus's product, but infringement is alleged on the basis that the proposed product is a bioequivalent copy. ¶47 col. 10:1-11
...the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia. The complaint does not provide specific data on the dissolution rate of Zydus's product. This will be a central point for discovery based on the ANDA submission. ¶47 col. 10:11-18
  • Identified Points of Contention:
    • Technical Questions: A primary question is factual: does the formulation described in Zydus's confidential ANDA submission actually use edaravone particles that meet the specific D50 and D90 particle size ranges recited in claim 1? Furthermore, does the proposed generic product exhibit the dissolution rate specified in the claim? The infringement case hinges on the answer to these technical questions, which will be revealed during discovery.
    • Scope Questions (Product-by-Process): Claim 1 includes limitations on the product defined by the process of its creation (i.e., particle size and dissolution rate). A potential dispute may arise over whether Zydus's product, even if bioequivalent, is actually "prepared by" a process that results in a product with these specific claimed properties, or if it achieves bioequivalence through a different, non-infringing formulation.

V. Key Claim Terms for Construction

  • The Term: "dispersant"

    • Context and Importance: The identity and function of the dispersant are central to the patent's claimed solution for creating a stable and bioavailable suspension. The scope of this term will be critical in determining whether the excipients used in Zydus's formulation fall within the claim.
    • Evidence for a Broader Interpretation: The specification suggests a broad, functional definition, stating that "any dispersant that allows the edaravone particles to be well dispersed in water without causing the edaravone particles to form secondary agglomerates may be used" ’586 Patent, col. 4:11-15
    • Evidence for a Narrower Interpretation: The patent also provides a list of preferred examples (e.g., polyvinyl alcohol, methylcellulose) and describes specific functional tests, such as exhibiting a "transmission scattering light intensity of 1% or more" or a "contact angle of 80 degrees or less" ’586 Patent, col. 4:16-18 ’586 Patent, col. 4:47-49 A party could argue the term should be construed to require these specific properties, potentially narrowing its scope.

  • The Term: "prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm"

    • Context and Importance: This product-by-process language is a critical limitation. Practitioners may focus on this term because infringement depends on whether the accused product possesses the structural characteristics imparted by this process, namely the specific particle size distribution.
    • Intrinsic Evidence for Interpretation: The claim links the final suspension product to a manufacturing process involving particles of a specific size. The specification explains that controlling particle size is important for controlling the dissolution rate and achieving a "prompt drug effect" ’586 Patent, col. 10:3-18 A defendant might argue its product, even if bioequivalent, is made with particles outside the claimed ranges and therefore does not have the structure imparted by the claimed process, thus avoiding infringement.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Zydus will induce infringement by marketing the generic product with labeling that instructs physicians and patients on its administration for treating ALS, which is the patented use Compl. ¶50 Compl. ¶53
  • Willful Infringement: The willfulness allegation is based on Zydus's knowledge of the ’586 Patent, evidenced by its submission of a Paragraph IV certification against it. The complaint alleges that Zydus proceeded despite an "objectively high likelihood" of infringement, tracking the legal standard for enhanced damages Compl. ¶51

VII. Analyst’s Conclusion: Key Questions for the Case

  1. A central issue will be one of technical proof: Can Shionogi, through discovery of the confidential ANDA, demonstrate that Zydus's proposed generic suspension is not only bioequivalent but also meets the specific, quantitative limitations of Claim 1, particularly the D50/D90 particle size distribution and the dissolution rate?

  2. The case may also turn on a question of infringement scope: Assuming Zydus's product is bioequivalent, is that sufficient for infringement, or can Zydus prove it engineered its formulation to achieve that bioequivalence using a particle size distribution or other properties that fall outside the explicit boundaries defined in the patent's claims?